XSHG
600488
Market cap1.06bUSD
Oct 09, Last price
6.47CNY
1D
-0.77%
1Q
15.95%
Jan 2017
4.19%
IPO
11.59%
Name
Tianjin Tianyao Pharmaceutical Co.
Chart & performance
P/E
100.11
P/S
2.43
EPS
0.06
Div yield, %
1.50%
Shrs. gr., 5y
-0.19%
Rev. gr., 5y
-1.38%
Revenues
2.91b
-9.56%
Net income
71m
-47.12%
CFO
136m
-76.03%
Dividend
Jul 14, 20260.052 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tianjin Tianyao Pharmaceuticals Co., Ltd. is a Chinese enterprise primarily engaged in the research, manufacturing, and export of active pharmaceutical ingredients (APIs) across the Asian market. The company's core product offerings include APIs and formulated drugs for corticosteroid, cardio cerebrovascular, and analgesic applications. Its extensive portfolio of bulk drug substances encompasses numerous compounds such as dexamethasone and its various salts and esters, prednisone, prednisolone, flucinonide, halcinonide, triamcinolone and its derivatives, clobetasol propionate, betamethasone, and methylprednisolone. Based in Tianjin, China, Tianjin Tianyao Pharmaceuticals Co., Ltd. (SHSE: 600488) operates as a subsidiary of Jinhushen Biomedical Technology Co., Ltd.
Key people
Jian Chen
Chairman of the Board, General Manager · since 2017
Shiyan Ren
Chief Financial Officer, Director · since 2017
Jie Zhang
Chief Technology Officer, Executive Deputy General Manager, Director · since 2014
Keting Yao
Deputy General Manager · since 2017
Chunli Wang
Secretary of the Board · since 2014
Xiangli Feng
Director · since 2010
Mai Wang
Director · since 2013
Jianxin Fang
Independent Director · since 2008
Yongzhou Yu
Independent Director · since 2008
Zhiwen Zhao
Independent Director · since 2010
Headquarters & legal address
天津开发区西区新业九街19号
滨海新区, TJ 300000
CN
滨海新区, TJ 300000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||